PubRank

Yasushi Shigeoka

Author PubWeight™ 13.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells. Int J Oncol 2007 0.91
2 Elevated urinary 8-hydroxydeoxyguanosine, a biomarker of oxidative stress, and lack of association with antioxidant vitamins in chronic obstructive pulmonary disease. Respirology 2003 0.91
3 Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells. Oncol Rep 2005 0.90
4 Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit 2007 0.88
5 Expression of functional leukotriene B4 receptors on human airway smooth muscle cells. J Allergy Clin Immunol 2009 0.87
6 Loss of imprinting of PEG1/MEST in lung cancer cell lines. Oncol Rep 2004 0.86
7 Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int J Oncol 2008 0.86
8 Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor. Int J Oncol 2009 0.84
9 Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer. Int J Oncol 2004 0.82
10 Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 2004 0.80
11 Des-gamma-carboxy prothrombin (PIVKA-II)-producing mediastinal embryonal carcinoma with features of hepatoid differentiation. Anticancer Res 2005 0.78
12 Enhancement of cisplatin-induced cytotoxicity by ROCK inhibitor through suppression of focal adhesion kinase-independent mechanism in lung carcinoma cells. Int J Oncol 2003 0.78
13 [Cost-effectiveness of weekly paclitaxel for patients with advanced non-small cell lung cancer]. Gan To Kagaku Ryoho 2003 0.77
14 UFT plus vinorelbine in advanced non-small cell lung cancer: a phase I and an elderly patient-directed phase II study. J Thorac Oncol 2009 0.77
15 Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology 2003 0.76
16 Lung cancer arising in association with middle lobe syndrome. Anticancer Res 2006 0.76
17 ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol 2004 0.76
18 Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells. Oncol Rep 2010 0.76
19 The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients. Cancer J 2006 0.75
20 Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells. Oncol Rep 2008 0.75